vs
Side-by-side financial comparison of Elme Communities (ELME) and RHYTHM PHARMACEUTICALS, INC. (RYTM). Click either name above to swap in a different company.
Elme Communities is the larger business by last-quarter revenue ($62.1M vs $57.3M, roughly 1.1× RHYTHM PHARMACEUTICALS, INC.). RHYTHM PHARMACEUTICALS, INC. runs the higher net margin — -83.0% vs -198.9%, a 115.9% gap on every dollar of revenue. On growth, RHYTHM PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (36.9% vs 1.7%). Over the past eight quarters, RHYTHM PHARMACEUTICALS, INC.'s revenue compounded faster (48.5% CAGR vs 2.7%).
Elme Communities is a publicly traded U.S. real estate investment trust that primarily owns, operates and develops high-quality multifamily residential communities. It focuses on key growth markets across the U.S. Mid-Atlantic and Southeast, offering affordable to mid-tier housing options for diverse renter groups.
Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.
ELME vs RYTM — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $62.1M | $57.3M |
| Net Profit | $-123.5M | $-47.5M |
| Gross Margin | 61.1% | 91.6% |
| Operating Margin | -183.3% | -82.2% |
| Net Margin | -198.9% | -83.0% |
| Revenue YoY | 1.7% | 36.9% |
| Net Profit YoY | -4058.7% | -9.6% |
| EPS (diluted) | $-1.40 | $-0.73 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $57.3M | ||
| Q3 25 | $62.1M | $51.3M | ||
| Q2 25 | $62.1M | $48.5M | ||
| Q1 25 | $61.5M | $32.7M | ||
| Q4 24 | $61.3M | $41.8M | ||
| Q3 24 | $61.1M | $33.3M | ||
| Q2 24 | $60.1M | $29.1M | ||
| Q1 24 | $59.5M | $26.0M |
| Q4 25 | — | $-47.5M | ||
| Q3 25 | $-123.5M | $-52.9M | ||
| Q2 25 | $-3.6M | $-46.6M | ||
| Q1 25 | $-4.7M | $-49.5M | ||
| Q4 24 | $-3.0M | $-43.3M | ||
| Q3 24 | $-3.0M | $-43.6M | ||
| Q2 24 | $-3.5M | $-32.3M | ||
| Q1 24 | $-3.6M | $-141.4M |
| Q4 25 | — | 91.6% | ||
| Q3 25 | 61.1% | 89.3% | ||
| Q2 25 | 63.5% | 88.6% | ||
| Q1 25 | 64.2% | 88.8% | ||
| Q4 24 | 62.9% | 90.9% | ||
| Q3 24 | 63.5% | 88.5% | ||
| Q2 24 | 63.4% | 89.9% | ||
| Q1 24 | 63.5% | 89.2% |
| Q4 25 | — | -82.2% | ||
| Q3 25 | -183.3% | -102.6% | ||
| Q2 25 | 9.6% | -93.4% | ||
| Q1 25 | 7.8% | -143.7% | ||
| Q4 24 | 10.4% | -98.6% | ||
| Q3 24 | 11.0% | -132.0% | ||
| Q2 24 | 9.8% | -139.2% | ||
| Q1 24 | 7.5% | -538.7% |
| Q4 25 | — | -83.0% | ||
| Q3 25 | -198.9% | -103.1% | ||
| Q2 25 | -5.7% | -96.1% | ||
| Q1 25 | -7.6% | -151.4% | ||
| Q4 24 | -4.9% | -103.6% | ||
| Q3 24 | -4.9% | -131.2% | ||
| Q2 24 | -5.8% | -110.9% | ||
| Q1 24 | -6.1% | -544.4% |
| Q4 25 | — | $-0.73 | ||
| Q3 25 | $-1.40 | $-0.82 | ||
| Q2 25 | $-0.04 | $-0.75 | ||
| Q1 25 | $-0.05 | $-0.81 | ||
| Q4 24 | $-0.04 | $-0.71 | ||
| Q3 24 | $-0.03 | $-0.73 | ||
| Q2 24 | $-0.04 | $-0.55 | ||
| Q1 24 | $-0.04 | $-2.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $7.1M | $388.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $908.9M | $139.1M |
| Total Assets | $1.7B | $480.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $388.9M | ||
| Q3 25 | $7.1M | $416.1M | ||
| Q2 25 | $4.8M | $291.0M | ||
| Q1 25 | $6.4M | $314.5M | ||
| Q4 24 | $6.1M | $320.6M | ||
| Q3 24 | $4.8M | $298.4M | ||
| Q2 24 | $5.6M | $319.1M | ||
| Q1 24 | $4.2M | $201.2M |
| Q4 25 | — | $139.1M | ||
| Q3 25 | $908.9M | $148.8M | ||
| Q2 25 | $1.0B | $-11.9M | ||
| Q1 25 | $1.1B | $18.9M | ||
| Q4 24 | $1.1B | $21.7M | ||
| Q3 24 | $1.1B | $11.2M | ||
| Q2 24 | $1.1B | $39.3M | ||
| Q1 24 | $1.1B | $61.6M |
| Q4 25 | — | $480.2M | ||
| Q3 25 | $1.7B | $506.9M | ||
| Q2 25 | $1.8B | $372.7M | ||
| Q1 25 | $1.8B | $386.7M | ||
| Q4 24 | $1.8B | $392.3M | ||
| Q3 24 | $1.9B | $363.6M | ||
| Q2 24 | $1.9B | $381.8M | ||
| Q1 24 | $1.9B | $258.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $15.9M | $-25.4M |
| Free Cash FlowOCF − Capex | $7.2M | — |
| FCF MarginFCF / Revenue | 11.6% | — |
| Capex IntensityCapex / Revenue | 14.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $86.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-25.4M | ||
| Q3 25 | $15.9M | $-26.6M | ||
| Q2 25 | $29.8M | $-23.3M | ||
| Q1 25 | $16.2M | $-40.4M | ||
| Q4 24 | $95.2M | $-18.8M | ||
| Q3 24 | $20.7M | $-25.2M | ||
| Q2 24 | $28.9M | $-29.1M | ||
| Q1 24 | $21.2M | $-40.7M |
| Q4 25 | — | — | ||
| Q3 25 | $7.2M | — | ||
| Q2 25 | $21.1M | — | ||
| Q1 25 | $10.5M | — | ||
| Q4 24 | $47.9M | — | ||
| Q3 24 | $8.8M | — | ||
| Q2 24 | $21.0M | — | ||
| Q1 24 | $7.6M | — |
| Q4 25 | — | — | ||
| Q3 25 | 11.6% | — | ||
| Q2 25 | 34.1% | — | ||
| Q1 25 | 17.1% | — | ||
| Q4 24 | 78.1% | — | ||
| Q3 24 | 14.4% | — | ||
| Q2 24 | 34.9% | — | ||
| Q1 24 | 12.8% | — |
| Q4 25 | — | — | ||
| Q3 25 | 14.0% | — | ||
| Q2 25 | 14.0% | — | ||
| Q1 25 | 9.2% | — | ||
| Q4 24 | 77.4% | — | ||
| Q3 24 | 19.4% | — | ||
| Q2 24 | 13.1% | — | ||
| Q1 24 | 22.9% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ELME
| Residential Segment | $57.7M | 93% |
| Other | $4.4M | 7% |
RYTM
Segment breakdown not available.
